Joseph Jimmy
Internal Medicine, Aster DM Healthcare, Dubai, ARE.
Cureus. 2025 Jul 3;17(7):e87223. doi: 10.7759/cureus.87223. eCollection 2025 Jul.
This case describes a 44-year-old male with poorly controlled type 2 diabetes mellitus, dyslipidemia, and hypertension - hallmarks of metabolic syndrome - who demonstrated significant clinical improvement following the initiation of semaglutide, a glucagon-like peptide-1 receptor agonist (GLP-1 RA), after discontinuing sitagliptin. The patient had previously been treated with multiple oral hypoglycemic agents and basal insulin, yet continued to have inadequate glycemic and lipid control. Upon replacing sitagliptin with semaglutide, he experienced marked reductions in glycated hemoglobin, low-density lipoprotein cholesterol, and urine albumin-creatinine ratio, along with improvements in liver enzyme levels and stable renal function. This case highlights the pleiotropic benefits of GLP-1 receptor agonists and supports their role in the comprehensive management of metabolic syndrome.
本病例描述了一名44岁男性，患有控制不佳的2型糖尿病、血脂异常和高血压（代谢综合征的特征），在停用西他列汀后开始使用胰高血糖素样肽-1受体激动剂（GLP-1 RA）司美格鲁肽后，临床症状有显著改善。该患者此前曾接受多种口服降糖药和基础胰岛素治疗，但血糖和血脂控制仍不理想。在用司美格鲁肽替代西他列汀后，他的糖化血红蛋白、低密度脂蛋白胆固醇和尿白蛋白-肌酐比值显著降低，同时肝酶水平有所改善，肾功能稳定。本病例突出了GLP-1受体激动剂的多效性益处，并支持其在代谢综合征综合管理中的作用。
